Swiss Re Discloses New Targets Ahead of Accounting Method Transition
By Andrea Figueras
Swiss Re released a new guidance for next year as it will start reporting under IFRS as of 2024.
For the upcoming year and under the IFRS method, the Swiss reinsurer aims to reach net profit of more than $3.6 billion, of which the life and health business is expected to contribute $1.5 billion.
For the property and casualty reinsurance segment, Swiss Re expects to reach combined ratio of less than 87%, while it targets a combined ratio of less than 93% for the corporate solutions business.
The company also anticipates a return on equity of more than 14%.
The new accounting method will have a positive impact on the bottom line, as it will better reflect the earnings power of its life and health business, and on its balance sheet, the company said.
The transition will enable the company to avoid systemic accounting mismatches under the previously-used US GAAP accounting method, resulting in a higher equity position for shareholders, Swiss Re said.
Swiss Re also noted that it aims to return to sustainable dividend growth and that it will implement a reserving uncertainty allowance for new business, which is expected to have a negative impact on profit after tax in 2024 of around $0.5 billion.
For insurances, a reserving uncertainty allowance sets aside funds to cover future claims and liabilities.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
December 01, 2023 01:54 ET (06:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters